TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

T14/SI
Revenue Growth
-
Profit Growth
-
Net Margin
-
ROE
-
Financials
Announcements
Dividends
Buybacks
Corp Actions
Revenue & Profit
Financial Data
Date Type Period Title Sentiment
Dividend History
DateTypeAmountCurrencyEx-DatePayment Date
Buyback Activity
DateSharesAvg PriceTotal ($)Cumulative
DateTypeDetails

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED (T14/SI) — FY2025: Revenue CNY 4,917M, Profit 2,131M, EPS 277.0. Data: FY2014-FY2025, Q1, Q2, Q3 quarterly data.

Historical Annual Data (12 years)
FYRevenue (M)Net Profit (M)EPSTotal Assets (M)Total Equity (M)
FY20254,9172,131277.011,6907,100
FY20247,3072,229290.010,7697,850
FY2023---10,2306,652
FY20228,249862112.010,1576,582
FY20216,908769100.09,0676,546

Compare T14 with

vs Singtel vs Wilmar vs DBS vs SIA vs UOB vs QAF vs Micro-Mechanics vs UOL